Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
MzFL92xzudmEqven
